News - Nano Life Quest Sdn Bhd
Main menu:
News
Norgen Biotek's Phage DNA Isolation Kits
Phage DNA Isolation Kits
The only broad phage-specific DNA isolation kits in the market
Norgen’s Phage DNA Isolation Kit provides a rapid method for the isolation and purification of total DNA from bacteriophages propagated in bacteria grown in liquid cultures.
Isolates DNA From any Bacteriophage, Lambda, M13, T4, T7, Phi and any others….
New kits for AAV (adeno-associated virus) Purification and Quantification by Norgen Biotek, Canada
AAV Purification Kits
Norgen is pleased to provide a range of kits for rapid and simple concentration and purification of AAV vectors from cell lysates and/or cell culture media. These kits feature fast and simple procedures for concentrating and purifying AAV vectors. Purification is based on spin column chromatography using Norgen’s proprietary resin as an ion exchanger. Contaminating cellular debris is largely removed while contaminating DNA and RNA is reduced using enzymatic digestion. Vectors purified in this manner are highly active for use in in vitro transduction experiments, and are eluted into a small volume for use in downstream applications.
DeNovix Honored at Scientists’ Choice Awards® Best New Life Sciences Product 2015
World's Fisrt Absorbance & Fluorescence Combined!
DS-11 FX+ Spectrophotometer / Fluorometer Series now with Enhanced Best in Class Lower Detection Limits (0.75 ng/uL dsDNA & 0.04 mg/mL BSA) with commercial release of version 3.00 software.
Amoy Diagnostics Co. LTD. ROS1 Diagnostics Test Contributed To A Phase 2 Clinical Study Of Crizotinib In Lung Cancer
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported OxOnc Development LP (“OxOnc”) in the completion of a Phase 2 study of crizotinib (the “OxOnc Study”) in East Asian patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC).
The OxOnc Study met its primary objective of demonstrating a high overall response rate for crizotinib. It enrolled 127 ROS1-positive patients in the People’s Republic of China (PRC), Japan, Taiwan and South Korea by using AmoyDx® ROS1 gene fusions test, and is the largest ROS1-positive NSCLC cohort reported to date. Results from the OxOnc Study were presented at the recent 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. (http://oxonc.com/pdfs/OxOncRelease020713.pdf). ROS1 gene rearrangements occur in about 2.4 percent of Asian patients with NSCLC. An estimated 1.5 million new cases of NSCLC are diagnosed worldwide each year.
AATI: Did you hear about our agreement with PacBio?
Well let us tell you!
We are thrilled to share the news of our new partnership with Pacific Biosciences. This partnership allows the mutual promotion of our respective technologies facilitating long-read sequencing. The collaboration enables genomic discovery by streamlining the workflows for PacBio’s powerful platforms with the addition of the Fragment AnalyzerTM.
The incorporation of our products into the PacBio workflow will shorten QA/QC steps to an hour or less, shaving days off library preparation. AATI and PacBio are excited about the benefits our customers will see as a result of this partnership and the ensuing discoveries.
Fast, High-Resolution DNA Sizing with the Fragment Analyzer™ System [CLICK HERE]
